• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Worldwide vaccine inequality threatens to unleash the next COVID-19 variant
On a warm South African day in mid-November 2021, Dr. Angelique Coetzee examined a 29-year-old man complaining of extreme fatigue and severe headaches. The symptoms seemed more consistent with heat stroke than the sore throat and fever she had noticed in her patients with COVID-19. At the end of the day, after seeing several similar cases test positive for COVID-19, Dr. Coetzee, chair of the South African Medical Association, became convinced that something was amiss. Within a week, investigators determined that her patients were infected with a new variant possessing multiple mutations (McKeever,  2021), B.1.1.529 BA.1 or “Omicron”.
Source: International Journal of Infectious Diseases - August 17, 2022 Category: Infectious Diseases Authors: Richard L. Oehler, Vivian R. Vega Tags: Perspective Source Type: research

Global Vaccine Inequality Threatens to Unleash the Next COVID-19 Variant
On a warm South African day in mid-November 2021, Dr. Angelique Coetzee examined a 29-year-old man complaining of extreme fatigue and severe headaches. The symptoms seemed more consistent with heat stroke than the sore throat and fever she had noticed in her COVID-19 patients. By day's end, after seeing several similar cases test positive for COVID-19, Dr. Coetzee, chair of the South African Medical Association, became convinced that something was amiss. Within a week, investigators determined that her patients were infected with a new variant possessing multiple mutations (McKeever 2021), B.1.1.529 BA.1, or Omicron.
Source: International Journal of Infectious Diseases - August 17, 2022 Category: Infectious Diseases Authors: Richard L. Oehler, Vivian R. Vega Tags: Perspective Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news